AbbVie
ABBV
#36
Rank
NZ$672.06 B
Marketcap
NZ$380.39
Share price
0.25%
Change (1 day)
21.60%
Change (1 year)

The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โ€œABBVโ€.

EPS for AbbVie (ABBV)

EPS in 2026 (TTM): NZ$3.51

According to AbbVie's latest financial reports the company's current EPS (TTM) is NZ$3.52. In 2025 the company made an earnings per share (EPS) of NZ$4.10 a decrease over its 2024 EPS that were of NZ$4.15.

EPS history for AbbVie from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$3.51-14.3%
2025NZ$4.10-1.26%
2024NZ$4.15-11.86%
2023NZ$4.71-58.95%
2022NZ$11.462.49%
2021NZ$11.18121.58%
2020NZ$5.05-44.7%
2019NZ$9.1345.84%
2018NZ$6.269.72%
2017NZ$5.70-9.54%
2016NZ$6.3116.28%
2015NZ$5.42184.1%
2014NZ$1.91-57.15%
2013NZ$4.45

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
NZ$2.24-36.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$48.33 1,272.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$24.79 604.14%๐Ÿ‡บ๐Ÿ‡ธ USA
Biogen
BIIB
NZ$16.01 354.68%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
NZ$11.73 233.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$6.10 73.12%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
NZ$11.90 237.97%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
NZ$6.65 88.99%๐Ÿ‡ฌ๐Ÿ‡ง UK
Neurocrine Biosciences
NBIX
NZ$11.49 226.30%๐Ÿ‡บ๐Ÿ‡ธ USA